PMAT assays for detecting other autoantibodies in ANA-associated rheumatic diseases

PMAT assays for detecting other autoantibodies in ANA-associated rheumatic diseases

antibody-antigen interplay ought to be examined to perceive the standard of the antibody response

The severity of illness of Covid-19 is very variable, starting from asymptomatic to vital respiratory illness and demise. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) could hypothetically contribute to this variability. We herein studied if eCoV Nucleoprotein (N)-specific antibodies within the sera of sufferers with gentle or extreme Covid-19 are related to Covid-19 severity.

There have been comparable ranges of eCoV N-specific antibodies early and throughout the first month of an infection in Covid-19 sufferers with gentle and extreme signs, and wholesome SARS-COV-2-negative topics. These outcomes warrant additional research to research the potential function of eCoV-specific antibodies in immunity to SARS-CoV-2 an infection. This text is protected by copyright. All rights reserved.

PMAT assays for detecting different autoantibodies in ANA-associated rheumatic ailments

Systemic sclerosis (SSc) is a heterogeneous autoimmune illness related to a number of anti-nuclear antibodies (ANA), together with these within the classification standards (anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA Pol III).

Nevertheless, the presence of much less widespread antibodies akin to anti-fibrillarin (U3-RNP) that generate a clumpy nucleolar sample by HEp-2 oblique immunofluorescence assay (IFA, ICAP AC-9) are thought-about illness particular and are with scientific subsets of SSc, subsequently enjoying a job in prognosis and prognosis.

A selected and delicate anti-fibrillarin assay could be an vital addition to serological prognosis and analysis of SSc. The aim of this research was to guage a brand new particle-based multi-analyte expertise (PMAT) for the measurement of anti-fibrillarin antibodies.

A complete of 149 affected person samples had been collected together with 47 samples from France (Lyon and Paris, n = 32) and Italy (Careggi Hospital, Florence, n = 15) chosen primarily based on AC-9 HEp-2 IFA staining (> 1:640, clumpy nucleolar sample) and 102 non-SSc controls (inflammatory bowel illness (IBD) n = 20, Sjögren’s syndrome (SjS) n = 20, infectious illness (ID) n = 7, systemic lupus erythematosus (SLE) n = 17, rheumatoid arthritis (RA) n = 17, and wholesome people (HI) n = 21). All samples had been examined on the anti-fibrillarin PMAT assay (analysis use solely, Inova Diagnostics, USA).

Moreover, the 47 anti-fibrillarin constructive samples had been additionally examined on PMAT assays for detecting different autoantibodies in ANA-associated rheumatic ailments (AARD). Anti-fibrillarin antibody knowledge carried out by fluorescence enzyme immunoassay (FEIA, Thermo Fisher, Germany) was accessible for 34 samples. The anti-fibrillarin PMAT assay was constructive in 31/32 (96.9%, France) and 12/15 (80.0%, Italy) of samples preselected primarily based on the AC-9 IIF sample (distinction p = 0.09).

Collectively, the PMAT assay confirmed 91.5% (95% confidence interval (CI): 80.1-96.6%) sensitivity with 100.0% (95% CI: 96.4-100.0%) specificity in non-SSc controls. Robust settlement was discovered between PMAT and FEIA with 100.0% constructive qualitative settlement (34/34) and quantitative settlement (Spearman’s rho = 0.89, 95% CI: 0.77.9-0.95%, p < 0.0001). Though most anti-fibrillarin constructive samples had been mono-specific (69.8%), some expressed extra antibodies (specifically Scl-70, centromere, dsDNA, Ro52, Ro60, SS-B, Ribo-P, DFS70, and EJ).

In conclusion, this primary research on anti-fibrillarin antibodies measured utilizing a novel PMAT assay exhibits promising outcomes the place the brand new PMAT assay had excessive degree of settlement to FEIA for the detection of anti-fibrillarin antibodies. The provision of novel AFA assays akin to PMAT would possibly facilitate the scientific deployment, extra research, standardization efforts, and doubtlessly consideration of AFA for subsequent generations of the classification standards.

cuttingimagehistology
cuttingimagehistology

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 336

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 336

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-1mgEcoli 1 mg (E. coli)
EUR 4216.8
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-500gEcoli 500 µg (E. coli)
EUR 3013.2
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207)

VAng-Ly3238-50gEcoli 50 µg (E. coli)
EUR 2056.8
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein.

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

Anti-human PD-1, PE-labeled

71290-1 50 µg
EUR 355
Description: R-Phycoerythrin-labeled anti-PD-1 neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Histone H3 Methylation Antibody Panel Pack I – Active Genes

C10000
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3 Methylation Antibody Panel Pack I – Repression Genes

C10001
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3 Methylation Antibody Panel Pack II – Active Genes

C10002
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3 Methylation Antibody Panel Pack II – Repression Genes

C10003
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3 Methylation Antibody Panel Pack III – Active Genes

C10004
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3K4 Methylation Antibody Panel Pack

C10005
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3K9 Methylation Antibody Panel Pack

C10006
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3K27 Methylation Antibody Panel Pack

C10007
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3K36 Methylation Antibody Panel Pack

C10008
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3K79 Methylation Antibody Panel Pack

C10009
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3 Acetylation Antibody Panel Pack I

C10010
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3 Acetylation Antibody Panel Pack II

C10011
  • EUR 928.26
  • EUR 588.50
  • 4 x 25 µg
  • 4 x 25 ul

Histone H4K20 Methylation Antibody Panel Pack

C10012
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H4 Acetylation Antibody Panel Pack

C10013
  • EUR 754.26
  • EUR 470.80
  • 4 x 25 µg
  • 4 x 25 ul

Histone H3 Phosphorylation Antibody Panel Pack

C10014
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3R2 Methylation Antibody Panel Pack

C10015
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3R8 Methylation Antibody Panel Pack

C10016
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3R17 Methylation Antibody Panel Pack

C10017
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H3R26 Methylation Antibody Panel Pack

C10018
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

Histone H4R3 Methylation Antibody Panel Pack

C10019
  • EUR 754.26
  • EUR 470.80
  • 3 x 25 µg
  • 3 x 25 ul

DNMT3A Protein

E11000
  • EUR 971.76
  • EUR 618.20
  • 10 µg
  • 10 ul

TET1 Protein (Active)

E12002
  • EUR 387.12
  • EUR 225.50
  • 10 µg
  • 10 ul

DNMT3B Protein 

E14000
  • EUR 971.76
  • EUR 618.20
  • 10 µg
  • 10 ul

DNMT1 Protein 

E15000
  • EUR 971.76
  • EUR 618.20
  • 10 µg
  • 10 ul

HDAC1 Protein 

E24002
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC10 Protein 

E24003
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC11 Protein 

E24004
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC2 Protein 

E24005
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC3 Protein 

E24006
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC4 Protein 

E24007
  • EUR 968.28
  • EUR 616.00
  • 10 µg
  • 10 ul

HDAC5 Protein 

E24008
  • EUR 968.28
  • EUR 616.00
  • 10 µg
  • 10 ul

HDAC6 Protein 

E24009
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC7 Protein 

E24010
  • EUR 968.28
  • EUR 616.00
  • 10 µg
  • 10 ul

HDAC8 Protein 

E24011
  • EUR 968.28
  • EUR 616.00
  • 50 µg
  • 50 ul

HDAC9 Protein 

E24012
  • EUR 968.28
  • EUR 616.00
  • 10 µg
  • 10 ul

H3F3A Protein 

E35003
  • EUR 174.84
  • EUR 78.10
  • 50 µg
  • 50 ul

H4 Protein 

E35005
  • EUR 174.84
  • EUR 78.10
  • 50 µg
  • 50 ul

SOD1 Protein 

E70000
  • EUR 599.40
  • EUR 365.20
  • 25 µg
  • 25 ul

EpiMag HT (96-Well) Magnetic Separator

Q10002
  • EUR 416.70
  • EUR 258.50
  • 1/Pack
  • 1/Pack

EpiMag 96-Well Microplate (5/pack) 

Q10003
  • EUR 136.56
  • EUR 52.80
  • 5/pack
  • 5/pack

DNA Methylation Antibody Panel Pack I

C20000
  • EUR 458.46
  • EUR 270.60
  • each
  • 2 x 25 ul

Anti-Apaf-1 (human) Monoclonal Antibody (2E12)

M00889-1 100ug
EUR 518.4
Description: Rat Monoclonal Apaf-1 (human) Antibody (2E12). Validated in ELISA, IP, IF, WB and tested in Human.

Anti-EDG-1 Antibody

A01502-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for EDG-1 Antibody (S1PR1) detection.tested for WB in Human, Mouse, Rat.

Anti-ROBO-1 Antibody

A01530-1 100ug
EUR 546
Description: Rabbit Polyclonal ROBO-1 Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

Anti-Bag-1 Antibody

A02423-1 50 ul
EUR 476.4
Description: Rabbit Polyclonal Bag-1 Antibody. Validated in IP, IHC and tested in Bovine, Canine, Human, Mouse, Rat.

Anti-TUB 1 Antibody

A02917-1 100ug/vial
EUR 352.8

Anti-Dok-1 Antibody

A03039-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Dok-1 Antibody (DOK1) detection.tested for WB in Human, Mouse, Rat.

Anti-TFIIIB90-1 Antibody

A03761-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for TFIIIB90-1 Antibody (BRF1) detection.tested for WB in Human, Mouse.

Anti-Atrophin-1 Antibody

A03828-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Atrophin-1 Antibody (ATN1) detection. Tested with WB in Human, Mouse, Rat.

Anti-CNG-1 Antibody

A05494-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for CNG-1 Antibody (CNGA1) detection. Tested with WB in Human, Mouse, Rat.

Anti-Periphilin 1 Antibody

A06996-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Periphilin 1 Antibody (PPHLN1) detection.tested for WB in Human, Mouse.

Anti-Lyl-1 Antibody

A07491-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Lyl-1 Antibody. Validated in IHC and tested in Human, Mouse, Rat.

Anti-GLI-1 Antibody

A07972-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for GLI-1 Antibody (ACSS1) detection. Tested with WB in Human, Mouse, Rat.

Anti-Cerebellin 1 Antibody

A09176-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Cerebellin 1 Antibody (CBLN1) detection. Tested with WB in Human, Mouse, Rat.

Anti-DOC-1 Antibody

A09467-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for DOC-1 Antibody (CDK2AP1) detection. Tested with WB in Human, Mouse.

Anti-NPDC-1 Antibody

A12846-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for NPDC-1 Antibody (NPDC1) detection. Tested with WB in Human, Mouse, Rat.

Anti-PAI-1 Antibody

A00637-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for PAI-1 Antibody (SERPINE1) detection.tested for WB in Human, Mouse, Rat.

Anti-Flk-1 Antibody

A00901-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Flk-1 Antibody (KDR) detection.tested for WB in Human, Mouse.

Anti-PARP-1 Antibody

A00122-1 100ul
EUR 476.4
Description: Rabbit Polyclonal PARP-1 Antibody. Validated in ELISA, IP, IF, WB and tested in Human, Mouse.

Anti-Presenilin 1 Antibody

A00138-1 100ul
EUR 476.4
Description: Rabbit Polyclonal Antibody for Presenilin 1 Antibody (PSEN1) detection. Tested with WB, IHC in Human, Mouse, Rat.

Anti-P-glycoprotein (human) Monoclonal Antibody (JSB-1)

M00049-1 125ug
EUR 703.2
Description: Mouse Monoclonal P-glycoprotein (human) Antibody (JSB-1). Validated in IF and tested in Human.

ACE2, His-Tag Protein

E80019
  • EUR 612.70
  • EUR 1437.70
  • 20 ul
  • 100 ul

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag

E80024
  • EUR 635.80
  • EUR 4995.10
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion

E80026
  • EUR 588.50
  • EUR 823.90
  • 20 ul
  • 50 ul

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag

E80027
  • EUR 635.80
  • EUR 4087.60
  • 1 ml
  • 100 ul

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028
  • EUR 388.30
  • EUR 860.20
  • 20 ul
  • 100 ul

Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit

YLA4051HU-48T 48T
EUR 435

Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit

YLA4051HU-96T 96T
EUR 562.5

Anti-HLA-G (human) Monoclonal Antibody (MEM-G/1)

M01235-1 100ug
EUR 476.4
Description: Mouse Monoclonal HLA-G (human) Antibody (MEM-G/1). Validated in IHC, WB and tested in Human.

Recombinant Caenorhabditis Elegans clec-161 Protein (aa 21-862)

VAng-Ly3239-inquire inquire Ask for price
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 161 (clec-161), partial, recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-1mgEcoli 1 mg (E. coli)
EUR 4893.6
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-500gEcoli 500 µg (E. coli)
EUR 3474
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313)

VAng-Ly3240-50gEcoli 50 µg (E. coli)
EUR 2370
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-1mgEcoli 1 mg (E. coli)
EUR 4200
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-500gEcoli 500 µg (E. coli)
EUR 2997.6
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225)

VAng-Ly3241-50gEcoli 50 µg (E. coli)
EUR 2040
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein.

Anti-Neurexin 1/NRXN1 Antibody

A01490-1 100ug/vial
EUR 400.8

Anti-Hexokinase 1/HK1 Antibody

A01504-1 100ug/vial
EUR 400.8

Anti-Synaptotagmin 1/SYT1 Antibody

A02314-1 100ug/vial
EUR 400.8

TOP-Plus to wszechstronna platforma biosensoryczna do monitorowania trwałości przeciwciał SARS-CoV-2

Background: Low preliminary SARS-CoV-2 antibody titers dropping to undetectable ranges inside months after an infection have raised issues over long run immunity. Each the antibody ranges and avidity of the antibody-antigen interplay ought to be examined to perceive the standard of the antibody response.

Strategies: A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay constructed into the beforehand described SARS-CoV-2 TOP assays that measured complete antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a flexible biosensor platform. TAb and SNAb ranges had been in contrast with avidity in beforehand contaminated people at 1.three and 6.2 months post-infection in paired samples from 80 COVID-19 sufferers. Sera from SARS-CoV-2 vaccinated people had been additionally evaluated for antibody avidity.

Outcomes: The newly designed avidity assay on this TOP panel correlated properly with a reference Bio-Layer Interferometry avidity assay (r=0.88). The imprecision of the TOP avidity assay was lower than 10%. Though TAb and neutralization exercise (by SNAb) decreased between 1.three and 6.2 months post-infection, the antibody avidity elevated considerably (P < 0.0001). Antibody avidity in 10 SARS-CoV-2 vaccinated people (median 28 days post-vaccination) was akin to the measured antibody avidity in contaminated people (median 26 days post-infection).

Conclusion: This extremely exact and versatile TOP-Plus panel with the power to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody ranges and avidity of particular person sera on one sensor can change into a beneficial asset in monitoring not solely SARS-CoV-2-infected sufferers, but additionally the standing of people’ COVID-19 vaccination response.

security concern of vaccination is the attainable improvement of antibody-dependent enhancement (ADE) of SARS-CoV-2 an infection

Vaccines are important to manage the unfold of extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and to guard the susceptible inhabitants. Nevertheless, one security concern of vaccination is the attainable improvement of antibody-dependent enhancement (ADE) of SARS-CoV-2 an infection.

The potential an infection of Fc receptor bearing cells akin to macrophages, would help continued virus replication and inflammatory responses, and thereby doubtlessly worsen the scientific final result of COVID-19.

Right here we reveal that SARS-CoV-2 and SARS-CoV neither infect human monocyte-derived macrophages (hMDM) nor induce inflammatory cytokines in these cells, in sharp distinction to Center East respiratory syndrome (MERS) coronavirus and the widespread chilly human coronavirus 229E.

Moreover, serum from convalescent COVID-19 sufferers neither induced enhancement of SARS-CoV-2 an infection nor innate immune response in hMDM. Though, hMDM expressed angiotensin-converting enzyme 2, no or very low ranges of transmembrane protease serine 2 had been discovered.

These outcomes help the view that ADE will not be concerned within the immunopathological processes related to COVID-19, nonetheless, extra research are obligatory to know the potential contribution of antibodies-virus complexes with different cells expressing FcR receptors.

Leave a Reply

Your email address will not be published. Required fields are marked *